92Bio

Executive Summary

92Bio is a private biotechnology company pioneering the development of novel multispecific T-cell engagers (TCEs) for cancer treatment. Founded in 2020 and headquartered in Cambridge, MA, the company leverages advanced antibody design and unique immune cell subsets, including γδ T-cells, to create fit-for-purpose therapeutics. By targeting both solid and hematologic tumors, 92Bio aims to transform patient outcomes with next-generation TCEs that address limitations of conventional T-cell redirecting approaches. The company's platform combines proprietary engineering capabilities with deep immunology insights to generate multispecific antibodies with optimized safety and efficacy profiles. While still in the preclinical to early clinical stage, 92Bio's differentiated approach targeting γδ T-cells—which offer innate antitumor activity and lower risk of cytokine release syndrome—positions it as an innovative player in the immuno-oncology space. The company's focus on multispecificity allows simultaneous engagement of multiple tumor-associated antigens, potentially overcoming antigen escape and broadening therapeutic index. With no disclosed clinical pipeline yet, 92Bio's progress will depend on advancing its lead candidates toward IND-enabling studies and initial clinical validation.

Upcoming Catalysts (preview)

• 2026IND Filing for Lead γδ T-Cell Engager Program70% success
• 2026Preclinical Proof-of-Concept Data at Major Conference (e.g., SITC, AACR)80% success
• TBDPartnership or Collaboration with Larger Pharma for Solid Tumor Indications50% success